Osteal Therapeutics Completes Series D Financing to Advance Orthopedic Infection Therapies
Osteal Therapeutics, Inc., a clinical-stage biopharmaceutical company, has completed an oversubscribed $50 million Series D financing led by Zimmer Biomet, with participation from Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners, and HM Capital. The funds will advance the development of Osteal’s therapies, particularly the NDA submission and commercial launch of VT-X7 for treating periprosthetic joint infection (PJI) of the hip and knee. VT-X7, which has shown positive results in the APEX and APEX-2 clinical trials, has received several FDA designations, including Breakthrough Therapy and Fast Track.
Osteal Therapeutics Completes Series D Financing to Advance Orthopedic Infection Therapies